BPH

BPH research examines inflammation's roleIs inflammation a potential target for the treatment of BPH? New research being presented at the 2014 AUA annual meeting may help answer this question.
Clinical Trial Watch April 2014This list of U.S.-based National Institutes of Health trials is derived from the NIH’s database and includes phase I-IV hypogonadism and BPH trials that are currently recruiting participants.
Ophthalmologists update advisory on alpha-blockersThe American Society of Cataract and Refractive Surgery and the American Academy of Ophthalmology have jointly issued an educational update about cataract surgery complications associated with systemic alpha-blockers based on the recent publication of two studies.
AUA Exhibit Hall Highlights: Orlando 2014This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.
PVP laser enabling BPH treatment for more patientsLaser photoselective vaporization prostatectomy is permitting surgical intervention for BPH in a widening array of patients, many of whom harbor comorbidities that would ordinarily exclude them from invasive procedures, according to a new multinational report.
CMS issues two codes for BPH implant procedureThe Centers for Medicare & Medicaid Services has issued two new codes that describe the UroLift implant procedure for the treatment of enlarged prostate in the April 2014 Update of the Hospital Outpatient Prospective Payment System (OPPS).
December 2013 Urology Products and ServicesThe latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.
Urology Product Preview November 2013Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.
FDA approves label addition for PDE-5 inhibitor
FDA approves label addition for PDE-5 inhibitorThe FDA has approved a product label addition for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) that involves its use with finasteride (Proscar).
Thulium vapoenucleation found safe, efficacious in BPHThulium vapoenucleation of the prostate provided significant and durable symptomatic improvement in benign prostatic obstruction, long-term follow-up of a clinical series showed.